Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.35 |
| ▸ | AURKA | O14965 | 6/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.30 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9931391 | 0.90 | BRAF (0.42) | BRAFTP53LMNAMAPTMEN1 | |
| SCHEMBL9930834 | 0.81 | BRAF (0.49) | BRAFTP53 | |
| SCHEMBL9930333 | 0.79 | BRAF (0.49) | BRAFTP53 | |
| SCHEMBL9930743 | 0.79 | CYP1A2 (0.35) | BRAFAURKAAURKBRPS6KB1LMNA | |
| SCHEMBL9930556 | 0.78 | BRAF (0.48) | BRAFTP53 | |
| SCHEMBL9930341 | 0.78 | BRAF (0.48) | BRAFTP53 | |
| SCHEMBL9930345 | 0.78 | BRAF (0.37) | BRAFTP53LMNAMAPT | |
| SCHEMBL9930124 | 0.78 | BRAF (0.48) | BRAFTP53MEN1KMT2A | |
| SCHEMBL10251286 | 0.78 | BRAF (0.57) | BRAF | |
| SCHEMBL9930496 | 0.77 | BRAF (0.39) | BRAFAURKAAURKBRPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885AURKA 1013/4885AURKB 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.